Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Rafael White"'
Autor:
Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn
Publikováno v:
Blood. 140:6635-6637
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f30e81e8dd7a65ebbbce80a7d460274d
https://doi.org/10.1182/blood-2022-162447
https://doi.org/10.1182/blood-2022-162447
Autor:
Veerendra Munugalavadla, Gary de Jesus, Aleksandra Markovets, Qinwen Liu, Oliver Venn, Rafael White, Giulia Fabbri, Paul Labrousse, Dan Stetson, Brian Dougherty, Darren Hodgson, Jill Walker, Anas Younes, Daniel Auclair
Publikováno v:
Cancer Research. 83:3369-3369
Introduction: Minimal or measurable residual disease (MRD) is an emerging independent predictor of progression-free and overall survival in several hematologic diseases. Despite many different methods used in clinical trials, few assays have clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7790fed47f9602e932cbf7c70ba5a8d9
https://doi.org/10.1158/1538-7445.am2023-3369
https://doi.org/10.1158/1538-7445.am2023-3369
Autor:
Clare Sun, Melih Acar, David Jenkins, Barrett Nuttall, Rafael White, Veerendra Munugalavadla, Adrian Wiestner
Publikováno v:
Blood. 140:9847-9848
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3e9162a75f12ee193f54eea273e6d9f
https://doi.org/10.1182/blood-2022-159525
https://doi.org/10.1182/blood-2022-159525
Autor:
Andrew A. Mortlock, Ian W. Flinn, Barrett Nuttall, Kathleen A. Burke, Mark Roschewski, Hendrik-Tobias Arkenau, Melih Acar, Shringi Sharma, Brian Dougherty, Nakhle S. Saba, Veerendra Munugalavadla, Maria Udriste, Rafael White, Patrick M. Reagan, Sven de Vos, Graham P. Collins, Manish R. Patel
Publikováno v:
Blood. 138:1418-1418
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after prior autologous stem cell transplant (ASCT) or chimeric antigen receptor T-cell (CAR-T) therapy have poor outcomes with limited treatment options. Bruton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dcdbb9e7a63f1acc60e53e091984d8c9
https://doi.org/10.1182/blood-2021-147567
https://doi.org/10.1182/blood-2021-147567